Patent Grant
6986896
The present invention relates to methods of treating onychomycosis employing compositions with urea as the active ingredient. Onychomycosis refers to a fungal infection of the nail unit, defined as the nail matrix, bed or plate. The present invention also relates to the use of urea as an antifungal agent, and to methods of treating fungal conditions of the skin in humans with urea as a topical antifungal.
Urea has been long recognized as a cosmetic ingredient in formulations acting as a humectant and moisturizer. High concentrations of urea, such as 40%, are also known to have mild, antibacterial effect. At these strengths the antibacterial effects are said to be similar to those of antibiotics, with the further advantage that all the common organisms are susceptible and the possibility of resistant strains need not be seriously considered. There have been reports of keratolytic activity attributed to urea with the ability at high concentrations to solubilize and denature protein. Dermatological compositions containing from 21 to 40 wt-% urea for treating dry scaly skin have been described in U.S. Pat. No. 5,919,470.
Concentrated solutions of urea can change the conformation of protein molecules. A striking effect is upon the water-binding capacity of the horny layer of the skin: pieces of normal horny layer, or scales from ichthyotic or psoriatic skin that have been soaked in 30% urea solution take up much more water. This is important because in maintaining the flexibility of the horny layer and the softness of the skin, the water content of the horny layer matters much more than its oil content.
Fungal infections of the nail are notoriously difficult to treat. Traditional, topical therapies cannot penetrate the nail plate, and eradicate the infection in and under the nail bed; they are useful only in milder forms of the disease. Systemic antifungal drug therapy is associated with potentially harmful side effects. Since oral antifungals are distributed throughout the entire body, systemic side effects such as elevated liver enzymes, gastrointestinal disorders and skin rashes are not uncommon and may require expensive medical intervention and laboratory tests.
Topical formulations for treating fungal infections, such as onychomycosis, have recently been described in U.S. Pat. No. 6,281,239B1. The method employs the use of a combination of a known antifungal agent and a tissue softening composition containing 30 to 60 wt-% urea.
We have now found that urea may be used as the sole active ingredient in treating fungal infections.
The present invention relates to methods of treating onychomycosis employing compositions containing urea as the antifungal agent. The present invention relates to methods for treating onychomycosis in humans with urea. These methods include topically administrating to the nail area of a human a safe and effective amount of urea. Onychomycosis refers to a fungal infection of the nail unit, defined as the nail matrix, bed or plate.
Accordingly, the present invention is a method for treating onychomycosis by topically administering a safe and effect amount of urea in a pharmaceutically acceptable carrier.
Another embodiment of the invention is a method of treating fungal conditions of the skin by topically administering to the affected area of the skin of a patient in need thereof a safe and effective amount of urea in a pharmaceutically acceptable carrier.
The present invention is a method for treating or preventing onychomycosis. Such method includes administering to the nail area of a human in need of such treatment or prevention, a safe and effective amount of urea, for example, from about 10 to 60 wt-%, preferably about 30–50 wt-%, and particularly about 40 wt-%.
The present invention is a method for treating or preventing fungal conditions of the skin. Such method includes administering to the affected area of the skin of a human in need of such treatment or prevention, a safe and effective amount of urea, for example, from about 10 to 60 wt-%, preferably about 30–50 wt-%, and particularly about 40 wt-%.
The term “administering” as needed herein refers to any method which, in sound medical practice delivers the urea, e.g., 40% urea, to be treated in such a manner so as to be effective in the treatment of fungal conditions including, for example, onychomycosis. Preferably, the urea is administered topically in a single composition.
The phrase “safe and effective amount”, as used herein, means an amount of urea sufficient enough to significantly and positively modify the condition to be treated but low enough to avoid serious side effects, within the scope of sound medical advice. The safe and effective amount of the urea of the present invention will vary with the particular condition being treated, the severity of the condition, the duration of treatment, the particular pharmaceutically acceptable carriers utilized, and the like factors within the knowledge and expertise of the attending physician.
The method of the present invention typically involves administering the urea in an amount to cover the affected area. The specific preferred quantity of the urea depends upon the nature of the fungus and other skin or nail conditions also present.
Thus for example, the dosing of the agents includes up to 720 days of administration of a pharmaceutical composition of the present invention.
For the method of the present invention, the duration of administration of the urea will vary according to the specific extent of the fungal condition being treated, but typically is within the range of 90 to 210 days.
Topical Antifungal Agents
Typically, a topical antifungal agent consists of known naturally-occurring, synthetic or semi-synthetic composition, or mixture thereof, which is safe for use in the methods of the present invention, and is effective in killing or substantially inhibiting the growth of fungi, including but not limited to dermatophytes or yeast, Epidermophyton, Microsporum, Trichophyton and Candida albicans, and others.
Antifungal agents known to be useful for the treatment of onychomycosis include but are not limited to: topical creams, ointments, solutions, lacquers and gels containing as active agents, for example, amoroline, betadine, bifonazole, butenafine, clotrimazole, econazole nitrate, isoconazole, ketoconazole, miconazole nitrate, naftifine hydrochloride, oxiconazole, sulfanazole, terbinafine, ticonazole, tolnaftate, undecenoates and ciclopirox. The above antifungal topical compositions are known to those skilled in the art.
We have now surprisingly found urea to be an antifungal agent of equal potency to known antifungal agents. Urea was previously known as mentioned in the above Background section for its effectiveness for tissue softening and treating dry skin, without the need of traditional preservatives. Although there may have been some belief that urea had a mild antibacterial effect, nothing would have suggested that urea was an effective antifungal agent.
Thus, the present invention provides a method of treating fungal conditions and onychomycosis in a topical composition containing urea as the sole active ingredient.
Another embodiment of the invention is the administration of another known topical antifungal agent as above described with a safe and effective amount of urea. In this aspect, the safe and effective amount of urea is typically administered either before, after or concomitantly with a safe and effective amount of a topical antifungal agent.
In addition to containing a therapeutically antifungal effective amount of urea, the composition includes a pharmaceutically acceptable carrier containing dermatologically acceptable excipients as described in U.S. Pat. No. 5,919,470, which patent is incorporated herein by reference. The excipients particularly include skin protectants which include a combination of semi-solid and liquid petroleum fractions. The semi-solid skin protectant is contained in about 5.5 to about 20 wt-% and includes petrolatum or a synthetic or semi-synthetic hydrocarbon of the same nature as petrolatum. Mixtures of such ingredients can also be used. The preferred semi-solid material is petrolatum, commercially available from a wide variety of sources.
The liquid portion skin protectant is a liquid petrolatum and contained in the composition in about 10 to about 20 wt-%. This material can include any synthetic or semi-synthetic oleaginous liquid fraction. A preferred embodiment is mineral oil, which is a liquid mixture of hydrocarbons obtained from petroleum.
Another preferred ingredient encompassed in the composition of the present invention is propylene glycol which may be contained up to about 5 wt-% in the composition, preferably in the range of from about 1 to about 5 wt-%.
Various compositions, e.g. creams, lotions, and gels, containing urea as the sole active ingredient at various concentrations were tested against Trychophyton rubrum, a fungus typically implicated in Moccasin tinea pedis and onychomycosis, and compared to traditional antifungal compositions. A solution of the individual or combination products were inoculated with a known starting concentration of T. rubrum. These solutions were then retested at the specific time intervals to determine the residual microbial content. The decrease in observed microbial content was measured by standard serial dilution methods.
The decrease in the residual microbial content calculated as a percentage of its initial starting concentration is the percent kill rate reported in the following table.
The above tests indicate that urea is an effective antifungal agent.
Typical compositions employed in the present invention are for example:
A typical formulation representing the particular and most preferred embodiment of the present invention is illustrated as follows and is manufactured by mixing the ingredients below using well known conventional methods:
This is a continuation-in-part of application Ser. No. 10/103,213 of Mar. 20, 2002, now U.S. Pat. No. 6,673,842, for which benefit of priority is being claimed.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4295567 | Knudsen | Oct 1981 | A |
| 4514384 | Gallina | Apr 1985 | A |
| 4581351 | Berke et al. | Apr 1986 | A |
| 4607101 | Bernstein | Aug 1986 | A |
| 5334326 | Bostick | Aug 1994 | A |
| 5340836 | Reinhard et al. | Aug 1994 | A |
| 5407958 | Heath et al. | Apr 1995 | A |
| 5445823 | Hall et al. | Aug 1995 | A |
| 5525635 | Moberg | Jun 1996 | A |
| 5573765 | Reinhard et al. | Nov 1996 | A |
| 5632996 | Ramirez et al. | May 1997 | A |
| 5645428 | Yarborough | Jul 1997 | A |
| 5648389 | Gans et al. | Jul 1997 | A |
| 5707635 | Deckner et al. | Jan 1998 | A |
| 5843998 | Song et al. | Dec 1998 | A |
| 5853732 | Munden | Dec 1998 | A |
| 5899878 | Glassman | May 1999 | A |
| 5919470 | Valdez et al. | Jul 1999 | A |
| 5968533 | Porter et al. | Oct 1999 | A |
| 5993790 | Strauss | Nov 1999 | A |
| 6046178 | Silvetti | Apr 2000 | A |
| 6262117 | Sefton | Jul 2001 | B1 |
| 6281239 | Glassman | Aug 2001 | B1 |
| 6380236 | Glassman | Apr 2002 | B2 |
| 6429231 | Bhagwat et al. | Aug 2002 | B1 |
| 6488913 | Orlowski et al. | Dec 2002 | B2 |
| 6495602 | Bhagwat et al. | Dec 2002 | B1 |
| 6573301 | Glassman et al. | Jun 2003 | B1 |
| 6673842 | Bhagwat et al. | Jan 2004 | B2 |
| 6743417 | Glassman et al. | Jun 2004 | B2 |
| 20030138466 | Bhagwat et al. | Jul 2003 | A1 |
| 20030212127 | Glassman et al. | Nov 2003 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 9619186 | Jun 1996 | WO |
| WO-9823152 | Jun 1998 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030181526 A1 | Sep 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10103213 | Mar 2002 | US |
| Child | 10370666 | US |
